Table 2.
EA, CA, and types of errors produced when testing tigecycline susceptibility by Vitek2, Etest, and MTS compared to BMD
| Test method and isolate group | No. (%) of isolates with: |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| EA | CA |
VME |
ME |
mE |
|||||
| FDA | EUCAST | FDA | EUCAST | FDA | EUCAST | FDA | EUCAST | ||
| Vitek2 | |||||||||
| All isolates | 148 (61.4) | 116 (48.1) | 95 (39.4) | 0 (0) | 0 (0) | 22 (9.1) | 51 (21.2) | 103 (42.7) | 95 (39.4) |
| CR K. pneumoniae | 65 (52.0) | 57 (45.6) | 34 (27.2) | 0 (0) | 0 (0) | 10 (8.0) | 32 (25.6) | 58 (46.4) | 59 (47.2) |
| CR A. baumannii | 31 (55.4) | 14 (25.0) | 18 (32.1) | 0 (0) | 0 (0) | 7 (12.5) | 16 (28.6) | 35 (62.5) | 22 (39.3) |
| ESCR Enterobacteriaceae | 52 (86.7) | 45 (75.0) | 43 (71.7) | 0 (0) | 0 (0) | 5 (8.3) | 3 (5.0) | 10 (16.7) | 14 (23.3) |
| Etest | |||||||||
| All isolates | 229 (95.0) | 220 (91.3) | 173 (71.8) | 0 (0) | 0 (0) | 1 (0.4) | 2 (0.8) | 20 (8.3) | 66 (27.4) |
| CR K. pneumoniae | 121 (96.8) | 117 (93.6) | 81 (64.8) | 0 (0) | 0 (0) | 1 (0.8) | 1 (0.8) | 7 (5.6) | 43 (34.4) |
| CR A. baumannii | 52 (92.9) | 47 (83.9) | 39 (69.6) | 0 (0) | 0 (0) | 0 (0) | 1 (1.8) | 9 (16.1) | 16 (28.6) |
| ESCR Enterobacteriaceae | 56 (93.3) | 56 (93.3) | 53 (88.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (6.7) | 7 (11.7) |
| MTS | |||||||||
| All isolates | 187 (77.6) | 208 (86.3) | 165 (68.5) | 1 (0.4) | 8 (3.3) | 0 (0) | 0 (0) | 32 (13.3) | 68 (28.2) |
| CR K. pneumoniae | 103 (82.4) | 105 (84.0) | 80 (64.0) | 1 (0.8) | 6 (4.8) | 0 (0) | 0 (0) | 19 (15.2) | 39 (31.2) |
| CR A. baumannii | 50 (89.3) | 48 (85.7) | 35 (62.5) | 0 (0) | 1 (1.8) | 0 (0) | 0 (0) | 8 (14.3) | 20 (35.7) |
| ESCR Enterobacteriaceae | 34 (56.7) | 55 (91.7) | 50 (83.3) | 0 (0) | 1 (1.7) | 0 (0) | 0 (0) | 5 (8.3) | 9 (15.0) |